New research finds that cells are much more precise in how they ingest substances than previously thought, opening the door to potential treatments for several diseases.
Building on a legacy of groundbreaking advances in medicine and science, Weill Cornell Medicine today launched a $1.5 billion campaign that will harness emerging biomedical innovations to bring exemplary care to patients and create enduring change in medicine.
An advanced software tool for analyzing DNA sequences from tumor samples has uncovered likely new cancer-driving genes, in a study led by Weill Cornell Medicine researchers.
Celebrating graduation and each other, students in the Executive Master of Health Administration and Executive Master of Public Administration programs at the Cornell Jeb E. Brooks School of Public Policy received diplomas at a joyful ceremony in Willard Straight Hall.
The World Health Organization has selected the Division of Nutritional Sciences to lead systematic reviews and training supporting the development of WHO guidelines and research networks.
Reginald M. Ballantyne III, MBA ’67 is a prominent health care industry leader and longtime supporter of Cornell programs. He has endowed a scholarship that is the largest gift in the history of the Sloan Program in Health Administration in the Cornell Jeb E. Brooks School of Public Policy.
Adam Seth Litwin, an expert on issues involving technological change, work and workers in the healthcare sector, says because frontline caregivers are in such high demand, the healthcare sector may need to rely on prevention instead of treatment.
Researchers at Weill Cornell Medicine have developed a pre-clinical model of the leading cause of central vision loss in older individuals, dry age-related macular degeneration, and used it to identify new treatment modalities and drug targets.
The blood stem cell mutation, known as DNMT3A R882, leads to the growth of a large population of circulating blood cells that also contain this mutation.
